Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Extensive-stage small cell lung cancer is a fast-growing disease that has spread beyond the lung where it began. This stage is especially serious because the cancer is no longer confined to its original site and can involve distant organs.

Maintenance therapy is ongoing treatment given after an initial, more intensive treatment. In this study, patients first received Imfinzi and chemotherapy. Those whose cancer had not progressed then continued with Imfinzi alone or received Imfinzi together with Imdelltra.

The goal is to keep the cancer controlled for longer after the initial treatment works. The trial found that adding Imdelltra during this maintenance period extended median overall survival from 12.7 months with Imfinzi alone to 21.1 months with the combination. This suggests earlier use may help delay the disease’s return or progression, but the study did not compare the combination with every other first-line approach.

The combination extended median overall survival by 8.4 months. Patients receiving Imdelltra with Imfinzi lived a median 21.1 months, compared with 12.7 months for those receiving Imfinzi alone.

Median survival is not a promise for every patient. It means half of the patients in a treatment group lived at least about that long, while half lived less. The one-year results also showed a large difference: nearly 80% of patients taking both drugs were alive, compared with 53% receiving Imfinzi alone.

These results came from a trial of maintenance treatment. Patients had already received initial Imfinzi and chemotherapy, and their cancer had not progressed. The article reports that the combination reduced the risk of death by 58%. Longer follow-up could change the median figure, and the study did not test the combination against other first-line treatment approaches.

A 58% reduction in the risk of death compares outcomes between the two trial groups. It means the observed relative risk was 58% lower for patients receiving Imdelltra with Imfinzi than for those receiving Imfinzi alone during the study period.

That is different from saying 58% of patients were saved. The result does not identify a fixed percentage of individuals who avoided death, and it does not mean every patient gained the same benefit. The trial also reported median survival of 21.1 months with the combination versus 12.7 months with Imfinzi alone.

The result is a group-level comparison, not a personal guarantee. It also does not provide an absolute survival difference by itself. Nearly 80% of combination patients were alive at one year, compared with 53% on Imfinzi alone. Follow-up may further clarify how long the benefit lasts.

Extensive-stage small cell lung cancer is difficult because it grows quickly and has already spread beyond the lung. Even when chemotherapy initially works well for most patients, the disease often returns or progresses within months.

For example, immunotherapy has helped a small subset of patients maintain control for years. Most patients have not experienced such durable benefits. The challenge becomes even greater when cancer has spread to the brain or liver, areas linked with poorer treatment outcomes.

This pattern explains why the trial tested a maintenance combination after initial Imfinzi and chemotherapy. The aim was to keep the cancer controlled and extend survival after the first treatment phase. The study found longer median survival with Imdelltra plus Imfinzi, including benefits across patient subgroups. Longer follow-up will show whether the reported benefit remains sustained over several years.

Imdelltra and Imfinzi support the immune response in different ways. Imfinzi blocks PD-L1, a protein cancer cells use to evade immune attack. This helps remove the brakes on the immune system.

Imdelltra binds to DLL3 on cancer cells and CD3 on T cells. T cells are immune cells that can kill cancer. By binding both targets, Imdelltra brings T cells into close contact with tumor cells and helps activate them to attack.

A simple example is a two-part assault: Imfinzi makes immune action less suppressed, while Imdelltra helps direct T cells toward the cancer. The trial tested this combination as maintenance therapy after Imfinzi and chemotherapy. It found longer median survival than Imfinzi alone, but the study did not test whether the combination was better than other first-line treatment approaches.

Imdelltra is currently approved for patients whose small cell lung cancer progresses during or after platinum-based chemotherapy. The trial tested whether moving it earlier, into first-line maintenance treatment, could improve outcomes for patients already treated with Imfinzi and chemotherapy.

The results suggest a meaningful possible change. Median overall survival reached 21.1 months with Imdelltra plus Imfinzi, compared with 12.7 months for Imfinzi alone. Nearly 80% of patients who started both drugs were alive at one year, versus 53% receiving Imfinzi alone.

If confirmed, Imdelltra could become part of ongoing treatment soon after initial therapy rather than being reserved for later progression. Researchers saw benefits across groups, including patients with brain or liver spread. However, the study did not compare the combination with other first-line approaches, and longer follow-up is still needed.

The trial provides a direct comparison between Imdelltra plus Imfinzi and Imfinzi alone. It found a 58% reduction in the risk of death and longer median survival with the combination. That establishes an advantage over the study’s control group.

It does not establish superiority over other first-line treatment approaches because those treatments were not tested. No direct trial comparison means the results cannot show which option is best across all available strategies. Indirect comparisons can be misleading because studies may involve different patients, designs, or follow-up periods.

The findings therefore support the combination as a promising option, not as a proven winner over every alternative. Further evidence and longer follow-up could clarify its place in treatment. The article specifically notes that the study did not test whether the combination was better than other first-line approaches.